linjc16/ctgov huggingface dataset:
CArdioversion of Short Duration Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The study is aimed at testing the hypothesis whether atrial fibrillary rate (AFR), as a measure of atrial electrical remodeling assessed from surface ECG, is predictive of sinus rhythm maintenance after electrical cardioversion. Earlier studies performed in a retrospective fashion suggested that high AFR exceeding 350-360 fibrillations per minute is an independent predictor of AF relapse after cardioversion, particularly in patients with duration of AF episode not exceeding 30 days, however this hypothesis has not been tested in a prospective study. CASAF is an observational study that will enroll patients with short duration (< 30 days) AF admitted for electrical cardioversion. Admission ECG will be extracted in a digital format and processed off-line for estimation of AFR. AF relapse will be assessed during 6-weeks long follow-up period during which ECG control will be scheduled at week 1 and 6.

Official Title
-----------------
Study of ECG-derived Atrial Fibrillatory Rate for Prediction of the Outcome of Cardioversion of Short Duration Atrial Fibrillation

Conditions
-----------------
Atrial Fibrillation, Electrocardiography, Electrical Remodeling

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recurrent AF verified by at least one ECG recording prior to the index admission Known onset of symptoms within 30 days from index admission. Sinus rhythm ECG within 30 days prior to the index admission If onset of symptoms is unknown. If duration of the present AF episode >48 hours then thromboembolic risk should be minimized by either verifying that the patient is adequately anticoagulated according to the hospital routine or TEE performed to verify the lack of contraindications for electrical cardioversion. Echocardiography at any time since first onset of AF to verify the lack of significant valvular disease. Age older than 18 years. Exclusion Criteria: AF due to reversible cause or significant valvular heart disease Treatment with class I or III antiarrhythmic drugs within five half-lives of their elimination period. No amiodarone treatment within six months before admission Prior ablation of AF Unability to verify onset of symptoms within 30 days prior to the index admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Documentation of atrial fibrillation by ECG during follow up period after cardioversion | Primary outcome measure in the CASAF study is the number of patients who had relapse of atrial fibrillation during follow up. Primary analysis will be based on assessment the value of the ECG-derived atrial fibrillary rate < vs >= 350 f.p.m. for prediction of atrial fibrillation relapse during follow up | 6 weeks |
Acute Kidney Injury as a Risk Factor for Myocardial Injury After Non Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The incidence of acute kidney injury (AKI) postoperatively has been identified to be 21.6% in adults and 18.3% in hospitalized individuals. Surgery-related AKI is a severe complication that is related not only to short-term complications as increases in mortality rate and development of cardiac complications but also with complications on long term, such as development of chronic kidney disease. A better understanding of the mechanism of this hypthesis will lead to better management of this complication.

Detailed Description
-----------------
A randomized blinded prospective study included 206patients who the candidate for major surgery at South Egypt Cancer Institute, Assiut University, Assiut, Egypt. From April 2018 till April 2019, a detailed history and careful examination, routine laboratory investigations were done, Baseline ECG was recorded 24hours before surgery and 48hours postoperative at ICU.

Official Title
-----------------
Assessment of Acute Kidney Injury as a Risk Factor for Myocardial Injury After Non Cardiac Surgery in Critical Patients

Conditions
-----------------
Acute Kidney Injury (AKI)

Intervention / Treatment
-----------------
* Diagnostic Test: Kidney function test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who were candidates for major non cardiac surgery Exclusion Criteria: chronic cardiac diseases (myocardial ischemia, heart failure), Active severe infection, pregnancy, chronic kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Kidney function test|Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Creatinine level | Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours | every 12 hours |
Skin Imaging With Technologies in Development

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to develop non-invasive imaging modalities for assessment of skin. This is a pilot study which will use multiple imaging modalities to collect information on normal and lesional skin. The researchers understand that the purpose of this study is not to evaluate any particular treatment and an investigation of a new therapeutic intervention would require an additional protocol. Skin conditions to be studied include vascular lesions, pigmentary disorders, inflammatory conditions and neoplasms.

Detailed Description
-----------------
Normal and lesional skin will be assessed by the following imaging modalities: Laser Speckle Imaging can provide information about relative blood flow in a tissue. In skin it can be used to determine what areas have more blood flow and whether a particular intervention or treatment affects blood flow. Optical Coherence Tomography and Optical Doppler Tomography can provide pictures of blood vessels in an area of the body and can also tell how fast blood is flowing in that area. Photon Migration Spectroscopy can provide information about the amount of blood, oxygen, fat and water is in a tissue. Multi-Spectral Imaging can provide a 3 dimensional image of structures within the skin. Multiphoton Microscopy can provide images of structures of the skin.

Official Title
-----------------
Non-invasive Imaging Modalities for Assessment of Normal and Lesional Skin

Conditions
-----------------
Pigmented Skin Lesion of Uncertain Nature

Intervention / Treatment
-----------------
* Device: non-invasive imaging modalities for assessment of skin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult male or female 7 and older; able to carry out study instructions Exclusion Criteria: Younger than 7 years old pregnant woman breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Skin Imaging<br>non-invasive imaging modalities for assessment of skin | Device: non-invasive imaging modalities for assessment of skin<br>* skin imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect information on normal and lesional skin | Develop non-invasive imaging modalities for assessment of skin. | up to 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
human skin
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) followed by Sorafenib with TACE alone in patients with advanced hepatocellular carcinoma.

Official Title
-----------------
A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma

Conditions
-----------------
Advanced Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Procedure: TACE+Sorafenib
* Procedure: TACE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients > 18 years and <=70 years of age. at least 2 radiologic imaging showing characteristic features of hepatocellular carcinoma or cytologic/histologic evidence. tumor in liver and radiologically definable vascular invasion or extrahepatic metastasis. Criteria of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Hb ≥90g/L,white blood cell count ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³ Patients who can understand this trial and have signed information consent Exclusion Criteria: Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may affect the treatment of liver cancer. Patients with other diseases which may affect the treatment mentioned. Patients with a medical history of other malignant tumors. Subjects participating in other clinical trials. liver function:Child C. no pathological evidence of hepatocellular carcinoma.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: TACE+Sorafenib<br>TACE followed by Sorafenib | Procedure: TACE+Sorafenib<br>* TACE followed by Sorafenib<br>* Other names: TACE followed by Sorafenib;|
| Experimental: TACE<br>TACE alone | Procedure: TACE<br>* TACE alone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the overall survival rate of each group |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Sorafenib
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation

Study Overview
=================
Brief Summary
-----------------
Randomized, double blind, placebo controlled, prospective trial investigating the effect of erythropoietin in renal transplantation. The investigators postulate that erythropoietin reduces the risk of delayed graft function.

Detailed Description
-----------------
Randomized, double blind, placebo controlled, prospective trial in patients, receiving a kidney transplantation. Patients will be randomized to receive either Epoetin Beta (Neorecormon; Roche) or placebo. The primary endpoint will be delayed graft function. The anticipated duration of this trial is 2 year and the target sample size is 60 patients per arm.

Official Title
-----------------
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation

Conditions
-----------------
Patients Receiving a Kidney From a Non-Heart-Beating Donor

Intervention / Treatment
-----------------
* Drug: Epoetin beta


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients Receiving a kidney from a non-heart-beating donor category 3 Exclusion Criteria: Donor related factors: a prolonged warm ischaemic time (> 45 min); a cold ischaemic time of > 24 hours; serum creatinin of > 150 umol/l

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Epoetin beta<br> | Drug: Epoetin beta<br>* intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.<br>* Other names: Neorecormon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of delayed graft function and primary non function after kidney transplantation |  | within12 weeks after transplantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of dialysis treatment |  | within 12 weeks after transplantation | 
| incidence of acute rejection episodes |  | till one year after transplantation | 
| renal function at 3, 6 and 12 months |  | 3, 6 and 12 months after transplantation | 
| patient and graft survival |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
erythropoietin, kidney transplantation, delayed graft function
Virtual Biopsy Development to Identify Patient's Glioma Grade at the CHU of Poitiers Using Magnetic Resonance Imaging

Study Overview
=================
Brief Summary
-----------------
Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help to define the most adapted treatment.

Official Title
-----------------
Virtual Biopsy Development to Identify Patient's Glioma Grade at the CHU of Poitiers Using Magnetic Resonance Imaging

Conditions
-----------------
Development of the Virtual Biopsy, Tumor Grade, Artificial Intelligence Algorithms, Clinical, Radiological

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnostic test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age≥ 18 years, Patient with suspected glioma with prior imaging Subject free, with legal protection guardianship or curatorship; Enrollment in the French Social Security system; Informed consent signed by the patient Exclusion Criteria: Any contraindication to an MRI examination Legal protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons residing in a health or social establishment, adults under legal protection and finally patients in emergency situations Pregnant or lactating women, women of childbearing age who do not have effective contraception

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient's Glioma grade<br>magnetic resonance spectroscopy | Diagnostic Test: Diagnostic test<br>* The intervention occurs only one time (for 2h30), the MRI examination is divided as follow: Cinicial MRI (50 minutes) Research MRI (Phosphorus Spectroscopy, Sodium Imaging)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of the virtual biopsy in the context of gliomas through the use of statistical learning algorithms (artificial intelligence) compared to the biopsy. | Evaluate the diagnostic capabilities of artificial intelligence algorithms for virtual biopsy based on sensitivity and specificity | The MRI examination (for 2 hours 30 minutes) |
Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery

Study Overview
=================
Brief Summary
-----------------
To assess the association between neonatal SARS-CoV-2 antibody level at delivery and infant COVID-19 infection under age 6 months, and to identify predictive factors for neonatal antibody level at delivery.

Detailed Description
-----------------
This prospective observational study was conducted at the Rabin Medical Center, Israel. Mothers were enrolled from September 2021 to mid-February 2022, prior to transfer to the delivery room, and followed at the Maternity and Infant Ward. The study was approved by the institutional ethics committee (RMC- 0275-21). Written informed consent was obtained from the participating mothers. Inclusion criteria included maternal recipient of at least one dose of the BNT162b2 mRNA COVID-19 vaccine or prior microbiologically-confirmed natural COVID-19 infection. Exclusion criteria included (a) preterm birth at <34 weeks gestation; (b) congenital or acquired immune deficiency, including recipient of biological agents during the prior year to enrolment.

Official Title
-----------------
The Association of Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery With Infant COVID-19 Infection Under Age 6 Months: a Prospective Cohort Study

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: no intervantion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: included maternal recipient of at least one dose of the BNT162b2 mRNA COVID-19 vaccine or prior microbiologically-confirmed natural COVID-19 infection Exclusion Criteria: (a) preterm birth at <34 weeks gestation; (b) congenital or acquired immune deficiency, including recipient of biological agents during the prior year to enrolment.
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Unvaccinated, Prior natural COVID-19 infection<br>Unvaccinated, Prior natural COVID-19 infection | Other: no intervantion<br>* no intervention<br>|
| Vaccinated, No prior natural COVID-19 infection<br>Vaccinated, No prior natural COVID-19 infection | Other: no intervantion<br>* no intervention<br>|
| Vaccinated, Prior natural COVID-19 infection<br>Vaccinated, Prior natural COVID-19 infection | Other: no intervantion<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neonatal anti-spike antibody levels | Primary outcomes were neonatal anti-spike antibody levels at delivery and infant microbiologically-confirmed COVID-19 infection at age <6 months | 6 months |
Pilot Study on Deep Learning in the Eye

Study Overview
=================
Brief Summary
-----------------
Deep learning allows you to classify images using a self-learning algorithm. Transfer learning builds on an existing self-learning algorithm to enable image classification with fewer images. In this study, this technique will be applied to different image modalities in different syndromes. Retrospective study design.

Official Title
-----------------
Validation of a Transfer Learning Deep Learning Algorithm for Image Classification in Multiple Pathologies

Conditions
-----------------
Central Serous Chorioretinopathy, Diabetic Retinopathy, Cataract

Intervention / Treatment
-----------------
* Other: Image classification using deep learning algorithm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Availability of images, which allow discrimination. Exclusion Criteria: No availability of clear data on disease differentiation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No pathology<br> | |
| Pathology<br> | Other: Image classification using deep learning algorithm<br>* Image classification using deep learning algorithm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of Image classification by transfer learning algorithm |  | 1 year |